Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 50 of 181 entries
View as:
Phase: N/A
Priority: Normal
Start: 02/01/22
End: 04/01/24
Due: 04/01/25
Phase: N/A
Priority: Normal
Start: 12/01/20
End: 12/31/22
Due: 12/31/23
Phase: N/A
Priority: Normal
Start: 07/01/21
End: 07/01/23
Due: 07/01/24
Phase: N/A
Priority: Normal
Start: 06/30/13
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 07/01/21
End: 05/31/23
Due: 05/31/24
Phase: N/A
Priority: Normal
Start: 06/30/13
End: 12/31/16
Due: 12/31/17
Phase: N/A
Priority: Normal
Start: 11/15/21
End: 12/31/23
Due: 12/31/24
Phase: N/A
Priority: Normal
Start: 05/23/17
End: 05/28/20
Due: 05/28/21
Phase: N/A
Priority: Normal
Start: 09/01/21
End: 06/30/22
Due: 06/30/23
Phase: N/A
Priority: Normal
Start: 03/11/21
End: 10/03/22
Due: 10/03/23
Phase: N/A
Priority: Normal
Start: 11/05/22
End: 12/30/23
Due: 12/30/24
Phase: N/A
Priority: Normal
Start: 09/30/09
End: 01/31/13
Due: 01/31/14
Phase: N/A
Priority: Normal
Start: 10/01/22
End: 06/30/24
Due: 06/30/25
Phase: N/A
Priority: Normal
Start: 08/31/19
End: 07/31/21
Due: 07/31/22
Phase: N/A
Priority: Normal
Start: 10/20/23
End: 02/18/25
Due: 02/18/26
Phase: N/A
Priority: Normal
Start: 05/01/15
End: 01/31/20
Due: 01/31/21
Phase: N/A
Priority: Normal
Start: 03/31/12
End: 12/31/18
Due: 12/31/19
Phase: N/A
Priority: Normal
Start: 06/30/13
End: 12/31/16
Due: 12/31/17
Phase: N/A
Priority: Normal
Start: 06/30/23
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 01/01/24
End: 02/12/24
Due: 02/12/25
Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer
Phase: N/A
Priority: Normal
Start: 04/01/22
End: 09/01/29
Due: 09/01/30
Phase: N/A
Priority: Normal
Start: 01/31/16
End: 12/31/24
Due: 12/31/25
Phase: N/A
Priority: Normal
Start: 11/15/23
End: 12/31/24
Due: 12/31/25
Phase: N/A
Priority: Normal
Start: 07/01/16
End: 09/01/26
Due: 09/01/27
Phase: N/A
Priority: Normal
Start: 10/15/21
End: 12/30/22
Due: 12/30/23